YUCAIPA, Calif., Nov. 3, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the CEO, Scott Sand, will discuss the projected export sales of their new Oxyview Nasal Cannula this Friday, November 6, 2009 at 10:34AM Eastern Standard Time on The Money Channel's American Scene Radio with host Steve Crowley.
The company's recently issued Chinese patent, new distribution and expected ISO certification in December-2009 opens doors in the People's Republic of China. Chronic obstructive pulmonary disease (COPD) is a major epidemic in China, costing that society billions of dollars in health care expenditures and lost productivity from premature (and perhaps unnecessary) deaths every year. In 2000, the total cost of COPD and other smoking-related diseases in China was more than U.S. $5 billion and, in 2000, COPD was the second leading cause of mortality in China, trailing only cerebrovascular disease. Ingen has secured intellectual property rights in China, and upon ISO Certification in December-2009, projects a staggering $25M annual sales revenue in China along by 2012. The company has received an offer for China distribution from a major supplier and this will be announced later this month.
The company's pending European patents expected to issue in 2010, its new introduction at Germany's MEDICA this November-2009 and ISO Certification and CE Mark scheduled for December-2009 triggers generous revenues in Europe starting next year. In Europe estimates suggest that 10% of the population has COPD and is now the 5th leading cause of death in the European Communities. The social healthcare structure throughout Europe and for home oxygen care would recognize the cost savings through the use of the company's Oxyview Nasal Cannula and cost reductions as a result of a decrease in unnecessary home visits. Europe's medical care system indicates at least $25M in annual sales to Ingen by 2012.
The company's ISO Certification in December 2009 also allows its new distributor in Australia, Medical Industries Australia, to begin selling the new Oxyview Nasal Cannula immediately. COPD is costing the nation an estimated $818 to $898 million annually. This is a conservative estimate because it is based on 1993-94 figures extrapolated to the Year 2001. The addition of hidden costs could increase the estimate to more than $1 billion per year. It is the 4th leading cause of death for Australians. Annual sales in Australia should reach $1M by 2012, considering their medical care structure and economy of scale.
A growing elderly population, increase in home oxygen therapy and surgeries and an increase in Chronic Obstructive Pulmonary Diseases in the USA will result in demand for better efficiency and cost reductions in medical care. The elderly population in the USA age 75 and older in 2010 is expected to be almost 19M. In 2015 it is expected to increase to 20M and over the next 30 years will more than double. The Oxyview and Oxyview Nasal Cannula improves home oxygen therapy and reduces supplier costs by decreasing unnecessary service calls, thus reducing government expenditures related to treating COPD.
"Export sales will represent the majority of our $10M in 2010, and by 2012 reach $50M. The export sales are expected to out-perform domestic sales here in the USA as COPD is a more serious problem in China and Europe," Stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
http://www.moneychannel.tv/scas.php
http://ajrccm.atsjournals.org/cgi/content/full/176/8/732
http://www.efanet.org/copd/documents/manifesto-eng_000.pdf
http://www.efanet.org/copd/documents/statistics.pdf
About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.